Standard Biotools (LAB) revenue breakdown
By segment, Proteomics is the largest at 78% of fiscal 2024 revenue, growing 26% a year over 3 years.
By product, Product revenue is the largest at 72% of fiscal 2025 revenue, growing -5% a year over 3 years.
Revenue by segment
Fiscal years, as Standard Biotools reports them in its 10-K filings; fiscal 2024 total $174M.
| Segments | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|
| Proteomics | $68M | $53M | $64M | $136M | 78% |
| Genomics | $63M | $45M | $42M | $39M | 22% |
Revenue by product
Fiscal years, as Standard Biotools reports them in its 10-K filings; fiscal 2025 total $85M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | — | — | — | — | — | — | $72M | $79M | $65M | $62M | 72% |
| Services and other revenue | — | — | — | — | — | — | — | $27M | $26M | $24M | 28% |
| Product revenue | $89M | $84M | $94M | $95M | $100M | $100M | — | — | — | — | — |
| Service revenue | $15M | $17M | $19M | $21M | $23M | $26M | $24M | — | — | — | — |
| Development revenue | — | — | — | — | $9M | $3M | — | — | — | — | — |
| Collaboration and other revenue | — | — | — | $550,000 | $7M | $2M | $2M | — | — | — | — |
| License revenue | $238,000 | — | — | — | — | — | — | — | — | — | — |
| License revenue | — | $190,000 | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Standard Biotools reports them in its 10-K filings; fiscal 2025 total $85M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $30M | $33M | $37M | $40M | $38M | $43M | $33M | $36M | $36M | $36M | 42% |
| Americas | $56M | $49M | $51M | $47M | $75M | $64M | $44M | $46M | $37M | $31M | 36% |
| Asia-Pacific | $18M | $20M | $25M | $30M | $26M | $24M | $21M | $24M | $18M | $19M | 22% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LAB.
Open LAB in InvestinglyQuestions
Where does Standard Biotools make its money?
In fiscal 2024, by segment: Proteomics $136M, Genomics $39M.
From Standard Biotools's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.